Diamond EL, et al. - This work was planned to assess the efficacy and safety of vemurafenib in adults with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) enrolled in the VE-BASKET study. Findings revealed that in patients with BRAF V600–mutant ECD or LCH, vemurafenib has clinically meaningful and highly durable activity, warranting its consideration as a new standard of care for these patients.